Group 1 - ADC Therapeutics (ADCT) is recognized as a promising long-term penny stock with significant upside potential [1] - H.C. Wainwright analyst Robert Burns has lowered the price target for ADC Therapeutics from $8 to $7 while maintaining a Buy rating [1][2] - The price target adjustment follows a $60 million private placement financing announced on October 12, which is expected to close on October 27 [2] Group 2 - The proceeds from the private placement will support the commercial expansion of ZYNLONTA, a treatment for adults with relapsed B-cell lymphoma [2] - The financing is also aimed at strengthening the company's balance sheet and positioning it for long-term growth, with potential plans for a ZYNLONTA relaunch in 2027 [2] - ADC Therapeutics specializes in antibody drug conjugate technology, focusing on transforming treatment paradigms for patients with hematologic malignancies and solid tumors [3]